News and Trends 11 May 2017 Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with the patient’s own stem cells. Celyad is confident that the announcement of Fast Track Designation from the FDA will help it accelerate the search for a partner to develop C-Cure, a cell therapy for ischemic […] May 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 11 May 2017 Video: Meet the CEO developing Gene Therapy without Viral Vectors Eyevensys has found a way to deliver gene therapy without viral vectors. Clara caught up with the company’s CEO Raffy Kazandjian at BioTrinity to hear more. Eyevensys is based in Paris and has set itself the mission of enhancing current treatment options in the field of ophthalmology. The biotech has developed a new gene therapeutic approach that […] May 11, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2017 HIV Treatment Development Extends Life Expectancy by 10 Years According to a new study, the life expectancy of 20-year-olds starting HIV treatment has increased by a decade in the EU and North America. A massive new study from the UK was published today in The Lancet HIV. The study tracked how many HIV patients died during the first three years of HIV treatment, their cause […] May 11, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2017 Oxford Synbio Startup with Eyes on Therapeutics gets hold of CRISPR Synbio startup Oxford Genetics has licensed CRISPR from Emmanuelle Charpentier’s company, ERS Genomics, to boost its platform. Synthetic biology has so far remained on the fringe of biotech, but one company, Oxford Genetics, is demonstrating its use in therapeutics. To bolster its efforts, the startup has secured a nonexclusive license from ERS Genomics, which represents […] May 10, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2017 Roche’s Checkpoint Inhibitor Misfires in Late-Stage Trials Roche’s drug tecentriq just failed a late-stage Phase III study in bladder cancer, raising questions about its future as an anticipated blockbuster. Roche and Genentech have been pushing their checkpoint inhibitor tecentriq onto the market last year, going for a number of different indications including bladder cancer and non-small cell lung cancer (NSCLC). After the FDA handed out accelerated approval in May 2016, […] May 10, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Interview 10 May 2017 Video: Meet the CEO fighting Cancer with Mycobacteria Clara talked to Linda Summerton, CEO of Immodulon Therapeutics, about the company’s project of applying the microbiome to immuno-oncology. As R&D efforts in the microbiome gain traction, Clara talked to the head of one of the most valuable companies in the UK, Immodulon Therapeutics. When asked about Forbes’ valuation of her company at £400M, Linda Summerton laughed, “That’s […] May 10, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 10 May 2017 Incentivizing Charity: A New Way to Fund Cancer Research Here’s what we learned from a lecture by finance guru Roger Stein on a new cancer research funding model at the Charité BIH Entrepreneurship Summit in Berlin. “I’m not a scientist. I can’t build a drug. I’m never going to have enough money to fund even one of those [clinical] trials. But…all of us together […] May 10, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 9 May 2017 Video Interview: Meet the Oxford COO improving Tech Transfer Adam Stoten is the new COO of Oxford University Innovation. Philip caught up with him at BioTrinity in London to talk about tech transfer. Both from academic and industrial perspectives, tech transfer has a reputation for being an onerous process. But some organizations are working steadfastly to streamline it with great success, like Oxford University Innovation. […] May 9, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2017 AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal As part of the deal with Sanofi, Exscientia will tackle the discovery and design of new bispecific drugs using artificial intelligence algorithms. Exscientia, based in Scotland, is a company that uses artificial intelligence (AI) to develop new drugs faster. Its edge-cutting technology has caught the attention of Sanofi, which is offering Exscientia research funding and […] May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 9 May 2017 British Biotech Startup Partners with Takeda to Advance its T Cell Platform GammaDelta Therapeutics and Takeda have formed a strategic collaboration to develop a novel T cell platform, which is based on gamma delta (γδ) T cells. Based in London, GammaDelta Therapeutics builds on the work of Adrian Hayday and Oliver Nussbaumer of Kings College London and The Francis Crick Institute. Backed by the huge British VC […] May 9, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 9 May 2017 Scottish Shark Antibodies have caught Amgen’s Eye Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop shark-inspired antibodies delivered intracellularly. Elasmogen, based in Aberdeen, Scotland, develops soloMER‘s, which are the smallest naturally-occurring antibody binding domains. “They are remarkably stable,” Caroline Barelle told me this morning at BioTrinity in London. “They can survive extreme pH and temperatures […] May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2017 Hypermutation could be the Key to Biofuels – and Antibiotic Resistance Instead of taking a spa vacation, stressed out bacteria start mutating their DNA fast. This nearly suicidal behavior can yield a lucky survivor in nature. For us, it could mean new strategies for biofuel production and fighting antibiotic resistance, researchers say. Researchers from the Centre of Microbial and Plant Genetics at KU Leuven, in Belgium, are shining […] May 9, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email